New research outlines a critical driver in an immune cell's defense against melanoma

(Huntsman Cancer Institute) Researchers at Huntsman Cancer Institute have found critical new insights into how cells defend against melanoma. In a report published in Nature Communications, the team describes how an enzyme called nicotinamide phosphoribosyltransferase, or NAMPT, initiates antitumor activity. The researchers suggest that new therapies strengthening this pathway in immune cells could be the foundation for more effective treatments against melanoma.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news